Cargando…
Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders
BACKGROUND: Fibromyalgia (FM) is associated with sexual dysfunction, though much less is known about the sexual desire, and especially dyadic and solitary sexual desire, among women with fibromyalgia. AIM: To investigate on the one hand the global sexual desire, the dyadic sexual and solitary sexual...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847810/ https://www.ncbi.nlm.nih.gov/pubmed/34839232 http://dx.doi.org/10.1016/j.esxm.2021.100457 |
_version_ | 1784652126378524672 |
---|---|
author | Van Overmeire, Roel Vesentini, Lara Vanclooster, Stephanie Muysewinkel, Emilie Bilsen, Johan |
author_facet | Van Overmeire, Roel Vesentini, Lara Vanclooster, Stephanie Muysewinkel, Emilie Bilsen, Johan |
author_sort | Van Overmeire, Roel |
collection | PubMed |
description | BACKGROUND: Fibromyalgia (FM) is associated with sexual dysfunction, though much less is known about the sexual desire, and especially dyadic and solitary sexual desire, among women with fibromyalgia. AIM: To investigate on the one hand the global sexual desire, the dyadic sexual and solitary sexual desire, and on the other hand the association with depressive symptoms, fibromyalgia symptoms and medication use among women with fibromyalgia in Flanders, Belgium. METHODS: An online survey was spread through the Flemish league for Fibromyalgia Patients to be completed by women with fibromyalgia. The sexual desire inventory-2 (SDI-2) was used to measure sexual desire (global, dyadic, solitary), the VASFIQ for fibromyalgia symptoms, and the PHQ-2 for depressive symptoms, while also including questions on demographic factors (time since FM, age) and medication usage (antidepressants, pain medication, sleeping medication). MAIN OUTCOME MEASURE: Global sexual desire, dyadic sexual desire and solitary sexual desire were studied in relation to depressive symptoms, medication use and fibromyalgia symptoms. RESULTS: One hundred and three women with FM answered the survey. Depressive symptoms were significantly associated with a lower global, dyadic and solitary sexual desire, as was the use of antidepressant medication. The association between solitary sexual desire and depressive symptoms disappeared when controlled for antidepressant medication. Age, fibromyalgia symptoms nor time since diagnosis were significantly associated with any form of sexual desire. CONCLUSION: Depressive symptoms and antidepressant medication, and not fibromyalgia symptoms, were associated with decreased sexual desire of women with FM. As antidepressant medication and depressive symptoms are associated with a decreased sexual desire, more attention should be paid towards the mental health issues associated with fibromyalgia, as well as the prescription of antidepressant medication. This study is the first to investigate sexual desire among women with fibromyalgia in Flanders, and one of the few internationally to have done so. It is limited by its cross-sectional design, and for not providing information on men with FM. Van Overmeire R, Vesentini L, Vanclooster S, et al. Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders. Sex Med 2022;10:100457. |
format | Online Article Text |
id | pubmed-8847810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88478102022-02-22 Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders Van Overmeire, Roel Vesentini, Lara Vanclooster, Stephanie Muysewinkel, Emilie Bilsen, Johan Sex Med Original Research BACKGROUND: Fibromyalgia (FM) is associated with sexual dysfunction, though much less is known about the sexual desire, and especially dyadic and solitary sexual desire, among women with fibromyalgia. AIM: To investigate on the one hand the global sexual desire, the dyadic sexual and solitary sexual desire, and on the other hand the association with depressive symptoms, fibromyalgia symptoms and medication use among women with fibromyalgia in Flanders, Belgium. METHODS: An online survey was spread through the Flemish league for Fibromyalgia Patients to be completed by women with fibromyalgia. The sexual desire inventory-2 (SDI-2) was used to measure sexual desire (global, dyadic, solitary), the VASFIQ for fibromyalgia symptoms, and the PHQ-2 for depressive symptoms, while also including questions on demographic factors (time since FM, age) and medication usage (antidepressants, pain medication, sleeping medication). MAIN OUTCOME MEASURE: Global sexual desire, dyadic sexual desire and solitary sexual desire were studied in relation to depressive symptoms, medication use and fibromyalgia symptoms. RESULTS: One hundred and three women with FM answered the survey. Depressive symptoms were significantly associated with a lower global, dyadic and solitary sexual desire, as was the use of antidepressant medication. The association between solitary sexual desire and depressive symptoms disappeared when controlled for antidepressant medication. Age, fibromyalgia symptoms nor time since diagnosis were significantly associated with any form of sexual desire. CONCLUSION: Depressive symptoms and antidepressant medication, and not fibromyalgia symptoms, were associated with decreased sexual desire of women with FM. As antidepressant medication and depressive symptoms are associated with a decreased sexual desire, more attention should be paid towards the mental health issues associated with fibromyalgia, as well as the prescription of antidepressant medication. This study is the first to investigate sexual desire among women with fibromyalgia in Flanders, and one of the few internationally to have done so. It is limited by its cross-sectional design, and for not providing information on men with FM. Van Overmeire R, Vesentini L, Vanclooster S, et al. Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders. Sex Med 2022;10:100457. Elsevier 2021-11-25 /pmc/articles/PMC8847810/ /pubmed/34839232 http://dx.doi.org/10.1016/j.esxm.2021.100457 Text en Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Van Overmeire, Roel Vesentini, Lara Vanclooster, Stephanie Muysewinkel, Emilie Bilsen, Johan Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders |
title | Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders |
title_full | Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders |
title_fullStr | Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders |
title_full_unstemmed | Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders |
title_short | Sexual Desire, Depressive Symptoms and Medication Use Among Women With Fibromyalgia in Flanders |
title_sort | sexual desire, depressive symptoms and medication use among women with fibromyalgia in flanders |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847810/ https://www.ncbi.nlm.nih.gov/pubmed/34839232 http://dx.doi.org/10.1016/j.esxm.2021.100457 |
work_keys_str_mv | AT vanovermeireroel sexualdesiredepressivesymptomsandmedicationuseamongwomenwithfibromyalgiainflanders AT vesentinilara sexualdesiredepressivesymptomsandmedicationuseamongwomenwithfibromyalgiainflanders AT vancloosterstephanie sexualdesiredepressivesymptomsandmedicationuseamongwomenwithfibromyalgiainflanders AT muysewinkelemilie sexualdesiredepressivesymptomsandmedicationuseamongwomenwithfibromyalgiainflanders AT bilsenjohan sexualdesiredepressivesymptomsandmedicationuseamongwomenwithfibromyalgiainflanders |